{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T06:10:12Z","timestamp":1756447812560,"version":"3.44.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"Aim<\/jats:title>To investigate the efficacy and safety of standard dose and low-dose rituximab combined with corticosteroids and cyclophosphamide in the treatment of acquired haemophilia A.<\/jats:p><\/jats:sec>Methods<\/jats:title>A retrospective analysis was conducted on the clinical manifestations, laboratory tests, diagnosis and treatment process, and efficacy of 11 patients with acquired haemophilia A.<\/jats:p><\/jats:sec>Results<\/jats:title>Among the 11 patients, there were 6 males and 5 females with median age 64 years old (29-88 years); 11 patients had no underlying diseases before onset. Clinical manifestations include varying degrees of skin bruising, with 1 case accompanied by muscle hematoma, 1 case accompanied by gastrointestinal bleeding, and 1 case accompanied by abdominal hematoma; The laboratory examination showed an APTT prolongation of 85.97 \u00b1 27.26 seconds, which could not be corrected after incubation with normal plasma for 2 hours; FVIII: C activity 0.93 \u00b1 1.51%; The titer of FVIII inhibitor is 15.19 \u00b1 14.32BU; All 11 patients received a combination of prothrombin complex and fresh frozen plasma for hemostasis, with 1 patient receiving a single platelet transfusion; Among the 11 patients, 7 received a standard dose of rituximab (375mg\/m2\/w \u00d7 1w) combined with corticosteroids and cyclophosphamide regimen, and 4 received a low-dose rituximab (100mg\/w \u00d7 4w) combined with corticosteroids and cyclophosphamide regimen. The APTT recovery time was 37.3 \u00b1 8.6 days, 43.6 \u00b1 11.4 days (P&gt;0.05), and the FVIII activity increased to normal time was 30.2 \u00b1 9.8 days, 40.2 \u00b1 18.8 days (P&lt;0.05), respectively; The time for FVIII inhibitor to turn negative was 56.3 \u00b1 23.5 days and 63.9 \u00b1 29.1 days, respectively (P&lt;0.05); Four weeks after treatment, there was no statistically significant difference in the levels of B lymphocyte antigen, IgG, IgA, IgM, and incidence of adverse reactions between the two groups (P&gt;0.05).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Acquired haemophilia A is rare in clinical practice, with severe and common bleeding manifestations. Fresh frozen plasma combined with prothrombin complex had a good hemostatic effect. The standard dose of rituximab combined with corticosteroids and cyclophosphamide can quickly increase FVIII activity and eradicate FVIII inhibitors compared to the low dose of rituximab regimen, although there is no difference in efficacy and safefy between the two treatment regimens.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1642982","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:00Z","timestamp":1756446360000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Standard dose and low-dose rituximab combined with glucocorticoids and cyclophosphamide in the treatment of acquired haemophilia A"],"prefix":"10.3389","volume":"16","author":[{"given":"Mingxia","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Acquired Haemophilia Spanish Registry of the Spanish Society of Thrombosis and Haemostasis (SETH). Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003639","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2141.2003.04731.x","article-title":"A population-based, unselected, consecutive cohort of patients with acquired hemophilia A","volume":"124","author":"Collins","year":"2004","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14370","article-title":"Clinical characteristics and prognostic factors of acquired hemophilia A in Korea","volume":"27","author":"Kyun","year":"2021","journal-title":"Haemophilia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.11.005","article-title":"Acquired hemophilia A: diagnosis, aetiology, clinical spectrum and treatment options","volume":"10","author":"Shetty","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1326779","article-title":"Acquired hemophilia A","volume":"38","author":"Webert","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-Kuhne","year":"2009","journal-title":"Haemophilia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"CD011907","DOI":"10.1002\/14651858.CD011907","article-title":"Rituximab for eradicating inhibitors in people with acquired hemophilia A","volume":"8","author":"Remmington","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2210-8","article-title":"Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan","volume":"106","author":"Ogawa","year":"2017","journal-title":"Int J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.11.008","article-title":"Systematic review of the presentation of coagulation factor VIII inhibitors in rheumatic diseases: a potential cause of life-threatening hemorrhage","volume":"44","author":"O\u2019Connor","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/JBM.S77332","article-title":"Acquired hemophilia A: emerging treatment options","volume":"6","author":"Janbain","year":"2015","journal-title":"J Blood Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"109067","DOI":"10.1016\/j.thromres.2024.109067","article-title":"First-line immunosuppressive therapies for acquired hemophilia A: A 25-year cohort experience and network meta-analysis","volume":"241","author":"Rungjirajittranon","year":"2024","journal-title":"Thromb Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A low-dose rituximab regimen for first-line treatment of acquired haemophilia A","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-023-01657-y","article-title":"Combining low-dose rituximab and bortezomib as immunosuppressive therapy for acquired hemophilia A: 6 case series","volume":"40","author":"Fu","year":"2023","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1642982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:01Z","timestamp":1756446361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1642982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2025.1642982"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1642982","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1642982"}}